You can't see them, but trillions — maybe quadrillions — of them travel in and out of your practice every day. They're hungry, mysterious, community-oriented, and small. Very, very small. They ...

0001). Though no head-to-head data exist comparing elinzanetant and fezolinetant, Simon told Medscape Medical News the side effects with fezolinetant "tend to be gastrointestinal, whereas the side ...

Many of us with chronic obstructive pulmonary disease (COPD) have received medical devices to help with our breathing. At first, it seemed to me that some of these devices worked better than others.

Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could help patients manage their condition better - around a quarter ...

Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...

The FDA late Monday approved sales of Trelegy Ellipta, developed jointly by GlaxoSmithKline PLC and Innoviva Inc. It contains three widely used types of medicine to prevent — rather than treat ...